-- RBCは木曜日、人口増加の鈍化に伴い、一人当たりGDPの改善は継続するとの見通しを示した。また、四半期ベースでは、カナダの企業活動は概ねRBCの基本シナリオである緩やかな拡大と一致しており、第1四半期のGDP成長率は、RBC自身の予測である年率換算1.3%をわずかに上回り、カナダ銀行が4月の金融政策報告書で示した1.5%の予測とも一致していると指摘した。 カナダ銀行(BoC)については、RBCの基本シナリオは変更されていない。RBCは、BoCが2026年末まで金利を据え置くと予想しているが、BoCが4月の会合で、中東紛争によるエネルギー価格上昇が経済成長に及ぼす影響や、エネルギー価格を除く基調インフレ率の推移を注視していくとの見解を示したことを指摘した。 カナダの2月の国内総生産(GDP)成長率は前月比0.2%増となり、カナダ統計局の速報値およびRBCの予想と一致した。 1月に自動車業界で一時的な混乱が生じていた状況が緩和し始めたことで、財生産業とサービス業の両方が成長に貢献しました。製造業と卸売業は、以前のモデルチェンジによる操業停止後、自動車生産が正常化するにつれて回復し、小売GDPは0.2%増加しました。これは、個人消費の底堅さを示しています。RBCによると、2月の低迷は建設業、公共部門に集中しており、さらにエンターテインメント部門も減少しました。これは、オリンピック期間中のNHLの試合が2週間中断したことが原因とされています。 今後の見通しとして、3月のGDP速報値は「ほぼ横ばい」でした。これらの速報値は修正される可能性が高いものの、3月の初期指標は、第1四半期末まで成長の勢いが維持されたことを示唆しているとRBCは述べています。 労働時間は0.2%増加し、製造業の速報売上高は3月に3.5%増加しました。これは、原油価格の上昇を部分的に反映しているだけでなく、自動車生産のさらなる回復とも一致しています。RBCによると、石油および関連製品を除く卸売業の速報売上高も1.3%増加しました。
Related Articles
Research Alert: The Clorox Company Beats Estimates Driven By Household And International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CLX reported Q3 FY 26 net sales of $1.67B, flat Y/Y with organic sales down 1%, while adj. EPS of $1.64 grew 13% and beat consensus by $0.10. Gross margin contracted 140 bps to 43.2% due to elevated manufacturing costs and unfavorable mix, though disciplined expense management supported earnings. Mixed segment performance showed Household and International delivering growth of 3% and 8%, respectively, while Lifestyle declined 9% on lower consumption and inventory adjustments. Management updated FY 26 guidance expecting net sales to decline ~6% with organic sales down ~9%, including a 7.5%-pt ERP headwind. Adj. EPS guidance of $5.45-$5.65 represents a 27%-29% decline, with gross margin expected to contract 250-300 bps from GOJO inventory step-up and elevated energy costs. The April 1 GOJO acquisition expands the health portfolio though near-term integration costs pressure results. We believe the completed $580M digital transformation positions CLX for long-term operational improvements despite macro headwinds.
Research Alert: Rivn: Q1 Eps Ahead Of Consensus; 2026 Guidance Unchanged
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Rivian (RIVN) posted Q1 adjusted EPS of -$0.55 vs. -$0.41, ahead of the -$0.60 consensus. Revenue rose 11% to $1.38B ($10M ahead of consensus) on a 20% increase in total vehicle sales to 10,365 units, augmented by a 49% Y/Y increase in software and services revenue to $473M. RIVN's gross margin contracted 800 bps to 8.6%, but was ahead of the 8.4% consensus. The quarter's financial results reflect the company's strategic pivot toward broader market accessibility with the R2, though at the cost of near-term profitability. RIVN maintained prior 2026 guidance for adjusted EBITDA, vehicle deliveries, and capex. The company ended Q1 with cash of $4.8B, down from $6.1B at year-end 2025. Shares are trading 1% higher in after-hours trading. RIVN's Q1 earnings were ahead of expectations, although cash burn remains a key concern, with free cash flow deteriorating, driven by increased operating expenses and working capital consumption. Execution risks remain high given challenging demand facing the broader EV industry.
Research Alert: Rmd Posts Mixed Q3 Fy 26 With Solid Margin Expansion Despite Revenue Miss
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ResMed delivered mixed Q3 FY 26 results with revenue growing 11% to $1.43B, $20M below expectations, while non-GAAP EPS of $2.86 rose 21%, beating consensus by $0.06. Geographic performance showed broad strength with U.S./Canada/Latin America up 9% and Europe/Asia expanding 16%, while masks/accessories outpaced devices with 16% vs 9% growth. The standout highlight was gross margin expansion of 290 bps to 62.2% driven by manufacturing efficiencies and component cost improvements, demonstrating operational excellence in our view. The company continues advancing its digital health strategy with new product launches including the AirTouch F30i mask and plans for a 2027 Indiana distribution center. We expect the recently completed VirtuOx acquisition to strengthen diagnostic capabilities within ResMed's digital health ecosystem across 140+ countries, positioning the company well for continued growth in the expanding sleep and respiratory care market.